|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of ustekinumab,a human interleukin-12/23 monoclonal antibody,in patients with psoriasis:76-week result from randomized,double-blind,Placebo-controlled trial显示文摘 | Leonardi CL Kimball AB Papp KA | 2008 | Lancet2008，371，9625： | 1 |
| 2 | A global phase Ⅲ randomized controlled trial of etanercept in psoriasis:safety,efficacy,and effect of dose reduction显示文摘 | Papp KA Tyring S Lahfa M | 2005 | Br J Dermat2005，152，： | 1 |
| 3 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in pa- tients with psoriasis: 76-week results fi'om a randomised, dou- ble-blind, placebo-controlled trial (PHOENIX 1)显示文摘 | Leonardi CL Kimball AB Papp KA | 2008 | Lancet2008，371，9625： | 1 |
| 4 | Efficacy and safety of ustekinumab, a human intedeukin-12/23 monoclonal antibody, in pa- tients with psoriasis: 52-week results from a randomised, dou- ble-blind, placebo-controlled trial (PHOENIX 2)显示文摘 | Papp KA Langley RG Ibwohl M | 2008 | Lancet2008，371，9625： | 1 |
| 5 | Anti-IL-17 receptor antibody AMG 827 lesds to rapid clinical response in subjects with moderate to severe psoriasis:resuilts from a phase I,randomized,placebo-controlled trial显示文摘 | Papp KA Reid C Foley P | 2012 | J Invest Dermatol2012，132，10： | 1 |
| 6 | Efficacy and safety of ustekinumab,a human interleukin-12/23 mono- clonal antibody,in patients with psoriasis: 76-week resuhs from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1 ) 显示文摘 | Leonardi CL Kimball AB Papp KA | 2008 | Lancet2008，371，9625： | 1 |
| 7 | Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination显示文摘 | Papp KA Breuer K Meurer M | 2005 | J Am Acad Dermatol2005，52，2： | 1 |
| 8 | An in vivo eyecup preparation for the rat显示文摘 | Palhalmi J Szikra T Kekesi KA Papp A Juhasz G | 2001 | J Neurosci Methods2001，105，2： | 1 |
| 9 | Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial显示文摘 | Gordon KB Papp KA Hamihon TK | 2003 | JAMA2003，290，23： | 1 |
| 10 | Brodalumab, an anti-intedeu- kin-17-receptor antibody for psoriasis 显示文摘 | Papp KA Leonardi C Menter A | 2012 | N Engl J Med2012，366，13： | 1 |
| 11 | Efficacy and safety of tofacitinib,an oral Janus kinase inhibitor,in the treatment of psoriasis:a Phase 2b randomized placebo-controlled dose-ranging study显示文摘 | Papp KA MenterA Strober B | | 0，，03： | 1 |
| 12 | Efalizumab for the treatment of psoriatic arthritis 显示文摘 | Papp KA Caro I Leung HM | 2007 | J Cutan Med Surg2007，11，2： | 1 |
| 13 | Network meta-analysis of randomized controlled trials on esophagectomies in esophageal cancer:The superiority of minimally invasive surgery显示文摘BACKGROUND Previous meta-analyses,with many limitations,have described the beneficial nature of minimal invasive procedures.AIM To compare all modalities of esophagectomies to each other from the results of randomized controlled trials(RCTs)in a network meta-analysis(NMA).METHODS We conducted a systematic search of the MEDLINE,EMBASE,Reference Citation Analysis(http://gffzzb1f9d057b5954674sf96bc05co0bu6f69.ffgz.tsg.suse.edu.cn/)and CENTRAL databases to identify RCTs according to the following population,intervention,control,outcome(commonly known as PICO):P:Patients with resectable esophageal cancer;I/C:Transthoracic,transhiatal,minimally invasive(thoracolaparoscopic),hybrid,and robot-assisted esophagectomy;O:Survival,total adverse events,adverse events in subgroups,length of hospital stay,and blood loss.We used the Bayesian approach and the random effects model.We presented the geometry of the network,results with probabilistic statements,estimated intervention effects and their 95% confidence interval(CI),and the surface under the cumulative ranking curve to rank the interventions.RESULTS We included 11 studies in our analysis.We found a significant difference in postoperative pulmonary infection,which favored the minimally invasive intervention compared to transthoracic surgery(risk ratio 0.49;95%CI:0.23 to 0.99).The operation time was significantly shorter for the transhiatal approach compared to transthoracic surgery(mean difference-85 min;95%CI:-150 to-29),hybrid intervention(mean difference-98 min;95%CI:-190 to-9.4),minimally invasive technique(mean difference-130 min;95%CI:-210 to-50),and robot-assisted esophagectomy(mean difference-150 min;95%CI:-240 to-53).Other comparisons did not yield significant differences.CONCLUSION Based on our results,the implication of minimally invasive esophagectomy should be favored. | Lajos Szakó Dávid Németh Nelli Farkas Szabolcs Kiss Réka Zsuzsa Domotor Marie Anne Engh Péter Hegyi Balint Eross András Papp | 2022 | World Journal of Gastroenterology2022，28，30： | 1 |
| 14 | Efficacy and safety of secukinumab in the treatment of moderate - to - severe plaque psoriasis: a randomized, double - blind, placebo - controlled phase II dose ranging study 显示文摘 | Papp KA Langley RG Sigurgeirsson B | 2013 | British Journal of Dermatology2013，168，2： | 1 |
| 15 | Extended efalizumab therapy in improves chronic plaque psoriasis:Results from a randomized phase III trial显示文摘 | Leonardi CL Papp KA Gordon KB | 2005 | J AM ACAD Dermatol2005，52，3： | 1 |
| 16 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:76-week results from s randomized, double-blind, placebo-controlled trial (PHOENIX1) 显示文摘 | Leonardi CL Kimball AB Papp KA | 2008 | Lancet2008，371，9625： | 1 |
| 17 | A randomized,doubleblind,placebo-controlled phaseⅢstudy evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis显示文摘 | Krueger GG Papp KA Stough DB | 2002 | J Am Acad Dermatol2002，47，6： | 1 |
| 18 | Brodalumab, an anti -interleukin-17-receptor antibody for psoriasis 显示文摘 | Papp KA Leonardi C MenterA etal | 2012 | The New England journal of medicine2012，366，： | 1 |
| 19 | Consensus guidelines for the management of plaque psoriasis 显示文摘 | Hsu S Papp KA Lebwohl MG | 2012 | Arch Dermatol2012，148，1： | 1 |
| 20 | Anti-IL-17 receptor anti- body AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, random- ized, placebo-controlled trial 显示文摘 | Papp KA Reid C Foley P | 2012 | The Journal of investiga- tive dermatology2012，132，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员